Biogen Inc. (BIIB) — Analyst outlook / Analyst consensus target is. Based on 48 analyst ratings, the consensus is bullish — 25 Buy, 22 Hold, 1 Sell.
The consensus price target is $207.60 (low: $143.00, high: $250.00), representing an upside of 16% from the current price $178.96.
Analysts estimate Earnings Per Share (EPS) of $16.38 and revenue of $9.64B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $11.20 vs est $16.38 (missed -31.6%). 2025: actual $8.85 vs est $14.94 (missed -40.8%). Analyst accuracy: 42%.
BIIB Stock — 12-Month Price Forecast
$207.60
▲ +16.00% Upside
Average Price Target
Based on 48 Wall Street analysts offering 12-month price targets for Biogen Inc., the average price target is $207.60, with a high forecast of $250.00, and a low forecast of $143.00.
The average price target represents a +16.00% change from the last price of $178.96.
Highest Price Target
$250.00
Average Price Target
$207.60
Lowest Price Target
$143.00
BIIB Analyst Ratings
Buy
Based on 48 analysts giving stock ratings to Biogen Inc. in the past 3 months
EPS Estimates — BIIB
42%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $11.20
vs Est $16.38
▼ 46.2% off
2025
Actual $8.85
vs Est $14.94
▼ 68.8% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — BIIB
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $9.676B
vs Est $9.636B
▲ 0.4% off
2025
Actual $9.811B
vs Est $9.826B
▼ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
